180 related articles for article (PubMed ID: 31801570)
21. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
[TBL] [Abstract][Full Text] [Related]
22. Semiquantitative aspects of mast cells in normal skin and in neurofibromas of neurofibromatosis types 1 and 5.
Nürnberger M; Moll I
Dermatology; 1994; 188(4):296-9. PubMed ID: 8193404
[TBL] [Abstract][Full Text] [Related]
23. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
24. Creating a comprehensive research strategy for cutaneous neurofibromas.
Blakeley JO; Wolkenstein P; Widemann BC; Lee J; Le LQ; Jackson R; Stathis M; Verma SK
Neurology; 2018 Jul; 91(2 Suppl 1):S1-S4. PubMed ID: 29987129
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.
Wozniak B; Bove T; Zawada T; Calik J
Case Rep Dermatol; 2023; 15(1):194-201. PubMed ID: 37899948
[TBL] [Abstract][Full Text] [Related]
26. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
27. Melanocytic nevi are associated with neurofibromas in neurofibromatosis, type I, but not sporadic neurofibromas: a study of 226 cases.
Ball NJ; Kho GT
J Cutan Pathol; 2005 Sep; 32(8):523-32. PubMed ID: 16115049
[TBL] [Abstract][Full Text] [Related]
28. Vascular wall cells contribute to tumourigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study.
Friedrich RE; Holstein AF; Middendorff R; Davidoff MS
Anticancer Res; 2012 May; 32(5):2139-58. PubMed ID: 22593502
[TBL] [Abstract][Full Text] [Related]
29. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
[TBL] [Abstract][Full Text] [Related]
30. An Update on Neurofibromatosis Type 1: Not Just Café-au-Lait Spots, Freckling, and Neurofibromas. An Update. Part I. Dermatological Clinical Criteria Diagnostic of the Disease.
Hernández-Martín A; Duat-Rodríguez A
Actas Dermosifiliogr; 2016; 107(6):454-64. PubMed ID: 26979265
[TBL] [Abstract][Full Text] [Related]
31. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
[TBL] [Abstract][Full Text] [Related]
32. [Cutaneous manifestations of type 1 neurofibromatosis and their treatment].
Lantiéri L; Wolkenstein P
Ann Chir Plast Esthet; 1998 Aug; 43(4):445-54. PubMed ID: 9926476
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 proliferation-index (MIB-1) of neurofibromas in neurofibromatosis type 1 patients.
Friedrich RE; Hagel C; Brehme Z; Kluwe L; Mautner VF
Anticancer Res; 2003; 23(2A):953-5. PubMed ID: 12820329
[TBL] [Abstract][Full Text] [Related]
34. Glomus-like bodies within a neurofibroma: a novel neoplasm arising in neurofibromatosis type 1 or a coincidence?
Thareja S; Honigbaum A; Jukic D
J Cutan Pathol; 2015 Apr; 42(4):285-8. PubMed ID: 25384450
[TBL] [Abstract][Full Text] [Related]
35. Activation of PLCγ/AKT/IκBα/p65 signaling increases inflammation in mast cells to promote growth of cutaneous neurofibroma.
Xu J; Zhang H; Li C; Du H; Shu M; Jia J
Life Sci; 2019 Dec; 239():117079. PubMed ID: 31756343
[TBL] [Abstract][Full Text] [Related]
36. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas.
Karvonen SL; Kallioinen M; Ylä-Outinen H; Pöyhönen M; Oikarinen A; Peltonen J
Arch Dermatol; 2000 Oct; 136(10):1207-9. PubMed ID: 11030766
[TBL] [Abstract][Full Text] [Related]
37. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
38. Comedone-like changes overlying neurofibromas.
Laxmisha C; Thappa DM
Indian J Dermatol Venereol Leprol; 2007; 73(4):271-2. PubMed ID: 17675745
[No Abstract] [Full Text] [Related]
39. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
40. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
